Participation of Pars Isotope in the 34th European Nuclear Medicine Exhibition

Pars Isotope participated in the 34th Exhibition of European Association of Nuclear Medicine (EANM) to introduce its new and efficient products to the world community of nuclear medicine.
The 34th EANM exhibition with the presence of more than 700 experts from 180 radiopharmaceutical companies in the world was held virtually, from 20 to 23 October 2021, due to the outbreak of COVID-19 pandemic.
The goal of   Pars Isotope for participating in this scientific event was to introduce its latest efficient products in the field of cancer diagnosis and treatment. FAPI radiopharmaceutical and radiopharmaceutical kit is one of these products. This radiopharmaceutical has the ability to detect and treat tumors with FAP receptors which are expressed in more than 30 different types of cancer.
Two expert colleagues from Pars Isotope Company were online during the exhibition time to answer visitors’ questions about the products offered in our virtual booth.
This exhibition is held every year as a platform for publishing, discussing and introducing the latest results in the field of nuclear medicine. In fact, the purpose of EANM is the mutual exchange of knowledge related to the diagnosis, treatment and prevention of diseases through the use of radioactive materials in medicine. Pars Isotope, as the sole custodian of the production and supply of radiopharmaceuticals and radiopharmaceutical kits in Iran, is one of the main sponsors and participants of this exhibition.